SEC Tracker
Get the app

Adicet Bio ACET

Adicet Bio announced Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Phase 1 data for prula-cel showed durable responses in SLE patients
  2. FDA cleared IND and granted Fast Track Designation for ADI-212 in mCRPC
  3. Pivotal LN study startup activities underway with FDA meeting planned in 4Q/2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Adicet Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Immucell ICCC public float $51M, Jun 30, 2025
  2. Fitlife Brands FTLF public float $51M, Jun 30, 2025
  3. Cue Biopharma CUE public float $52M, Jun 30, 2025
  4. Avalo Therapeutics AVTX public float $54M, Jun 30, 2025
  5. Precision Biosciences DTIL public float $47M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.